medicijnen

ACCESS TO MEDICINES

Due to the rising prices of expensive medicines, access to medicines is increasingly becoming a problem, even in high-income countries like the Netherlands. This trend undermines the financial sustainability of the health system and hence compromises the right to health and equal opportunities for leading a healthy life.

Within this programme, we analyse the functioning of the system of medicines development, identify flaws in the system, and propose relevant (policy) changes, so that everyone, everywhere has access to high-quality, affordable medicines that meet their medical needs.

 

We push for Dutch and European policy makers to take a critical stance on medicine prices, transparency and public return on public investments. It is our intention that more EU Member States will support Dutch efforts to address the increasing prices of expensive medicines and look for policy options to counter this trend.

 

On the global level, we aim for the World Health Organization to fulfil its leading role in addressing the challenge of high drug prices worldwide, for example by proposing fair pricing models and by addressing the issue with Member States in a framework.

 

Thanks to our strong track record on access to medicines, we can rely on strong networks and good working relationships with various policy makers and politicians, both at Dutch and EU-level.

Current flaws in the system of medicines development

The fact that pharmaceutical companies can charge extremely high prices is due to the way in which medicines are developed and medicine prices are determined. This is done within a complex system of (inter)national and EU regulations in which major commercial interests play a role. Moreover, it is a system with many stakeholders (including government, health insurers, universities, hospitals, patient associations) with divergent and sometimes conflicting interests. The right to health is vulnerable in that system.

 

 

 

 

 

 

 

This infographic illustrates the system of medicines development. It also shows the current problems we identify and the (policy) changes we envision to get to a fair situation that guarantees equal access to fairly priced medicines, reimbursed by insurance. (Click the image to enlarge)

 

 

Change needed

  • The Dutch government should develop and propose more stringent legislation to create fair pricing models for medicines, and adopt requirements for transparency in pricing and cost at both national and EU levels. Alternative business models for the financing of research & development (R&D) in relation to drugs should be developed and promoted.
  • In order to guarantee the availability and accessibility of medicines, the Dutch government should set conditions regulating the way in which universities and other institutions use public funding for medical research and development; these conditionalities should include the promotion of accessibility and affordability when license agreements are made between universities and pharmaceutical companies.
  • Dutch policy-makers should have the political will to counteract the pharmaceutical industry lobby and check the undue influence exerted by the pharmaceutical industry over decisions taken by the Dutch government, the Dutch Medicines Evaluation Board and the EMA.
  • In order to inform decision-making procedures, the EMA should fully disclose all elements related to the development of medicines, including sources of funding and data on clinical trials.

 

Results of our advocacy

  • Just before the European elections in May 2019, we published the manifesto: ‘Health first’. Signatories of this manifesto range from politicians to political youth organizations and people who are active in health care.
  • A week before the European Elections, on 16 May 2019, we organised a public debate in the Red Hat: ‘Pharma’s Other Futures’. We spoke with researchers, doctors, politicians and experts about the current system of drug development and pricing, and alternative systems.
  • On Friday 10 May 2019, SOMO and Wemos published the report “Overpriced – Drugs developed with Dutch Public Funding” on public money invested in the development of new medicines. De Volkskrant and NPO Radio 1, among others, paid ample attention to our publication.
  • For earlier results, view our year overview 2018 and year overview 2017 or scroll through the news items on the website.

 

Ethical testing

Wemos has a track record of many years focusing on ethical clinical trials in low- and middle-income countries, and is one of the few organizations within the EU working on this topic on a policy level. One of our recent lobby successes is that the European Medicines Agency (EMA) is required to submit annual reports to the European Parliament detailing its efforts to ensure that medicines intended for the European market are tested ethically. In 2017 we published a report on unethical clinical trials in Africa.

Biomedical R&D: how can we do better for women and children?

If we want to achieve the Sustainable Development Goals (SDGS), we will need to do better for women and children. They are disproportionately exposed to poverty-related and neglected diseases. How can biomedical Research & Development (R&D) and policy improve this (gender) gap? Director Mariëlle Bemelmans will join a panel discussion on this topic at the [...]

“A missed opportunity”: Wemos’ reaction to VIG’s code of conduct 2020

With its new code of conduct, the Association Innovative Medicines (Vereniging Innovatieve Geneesmiddelen (VIG)) - the industry association for the Dutch branches of innovative pharmaceutical companies - has failed to set out a moral compass that answers urgent societal questions regarding high medicine prices and the pharmaceutical industry. This is Wemos' main message in a first [...]

This was the year 2019: our highlights

What an eventful year it has been. 2019 was filled with collaborations, workshops, new publications, media moments, and mutual learning sessions. And it was the anniversary year in which we looked back on 40 years of our work in protecting global public health. We’re ready for 2020! Last year we gained widespread media attention – [...]

The 2019 wins for the access to medicines movement

Tom Buis 2019 was an exciting year for those who work in the field of pharmaceutical policy. The topic of access to medicines is climbing higher on the political agenda. Not just in the Netherlands - where this topic has already been one of the political priorities for quite some time - but also in [...]

How do we license publicly funded medicines so that it will benefit the public?

Winne van Woerden Cases of soaring drug prices are frequently reaching the news lately. The current system of medicine development does not achieve what it was intended for: to provide equitable access to affordable and effective medicines for the patients that need them. Publicly funded research institutions can be of major influence in changing this [...]

Ella Weggen Wemos Kassa BNNVARA

Abuse of orphan designation leads to exorbitant drug price

Pharmaceutical company Lupin Europe is aiming to bring an existing medicine for a rare muscle disease on the market under a new name and at a much higher price. The Dutch public television programme 'Kassa', with more than one million viewers, reported this on November 2nd, showing how this pharmaceutical company uses public research to [...]